Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Palvella Therapeutics Inc PVLA

Healthcare Biotechnology
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to... see more

Recent & Breaking News (NDAQ:PVLA)

Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire November 11, 2025

Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference

GlobeNewswire November 6, 2025

Palvella Therapeutics Announces New QTORIN(TM) Product Candidate, QTORIN(TM) Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies

GlobeNewswire November 5, 2025

Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025

GlobeNewswire November 4, 2025

U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics' Phase 3 SELVA Trial of QTORIN(TM) Rapamycin for Microcystic Lymphatic Malformations

GlobeNewswire October 13, 2025

Palvella Therapeutics Announces Expansion of QTORIN(TM) Rapamycin's Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies

GlobeNewswire September 24, 2025

Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy

GlobeNewswire September 17, 2025

Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN(TM) Rapamycin for Cutaneous Venous Malformations

GlobeNewswire September 15, 2025

Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer

GlobeNewswire September 3, 2025

Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences

GlobeNewswire August 28, 2025

Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire August 14, 2025

Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025

GlobeNewswire August 7, 2025

Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

GlobeNewswire August 5, 2025

Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes

GlobeNewswire June 30, 2025

Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN(TM) Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%

GlobeNewswire June 23, 2025

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1-20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors

GlobeNewswire June 18, 2025

Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN(TM) Rapamycin for Microcystic Lymphatic Malformations

GlobeNewswire June 9, 2025

Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer

GlobeNewswire May 27, 2025

Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire May 15, 2025

Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

GlobeNewswire May 8, 2025